A new study published in the Journal of Neurosurgery highlights the potential of focused ultrasound technology in treating ...

New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according to a report. The report by GlobalData, a data and analytics company, showed ...

The Phase Ia trial is designed to assess the safety and efficacy of the company’s drug designed to target chemicals thought to be a cause of Alzheimer’s disease.

Recent studies implicate the immune system and a herpes virus as potential contributors to development of disease ...

Anavex Life Sciences' Blarcamesine trial raises concerns over approval. Learn why AVXL stock is undervalued, reflecting the ...

"During the early stage, it's possible for people with dementia to live well by taking control of their health and wellness, ...

ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on developing precision therapies for neurodegenerative diseases, today announced the initiation of its Phase 1b ...

The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...

A University of California, Irvine-led research team has discovered intricate molecular mechanisms driving the RNA processing ...

There is a potential link between Alzheimer's disease and the herpes simplex virus-1 (HSV-1), which is a common cause for ...

Dementia is a devastating condition that can affect everything from your thinking to your personality. And while you can't always control your risk of developing the disease, new research finds ...

Note: Alzheimer’s News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute ...